Point of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Global Market Report 2026

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market size has grown rapidly in recent years. It will grow from $0.88 billion in 2025 to $1 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising tuberculosis prevalence, adoption of conventional molecular diagnostics, increasing government health initiatives, expansion of hospital networks, growing awareness of early diagnosis benefits.

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market size is expected to see rapid growth in the next few years. It will grow to $1.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to demand for ultra-sensitive point-of-care testing, integration of ai with diagnostic assays, expansion of decentralized healthcare, investment in rapid nucleic acid amplification technologies, increasing funding for tuberculosis control programs. Major trends in the forecast period include rapid point-of-care testing, ultra-sensitive nucleic acid amplification, automated diagnostic platforms, compact & portable test devices, integration with electronic health records.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market in the coming years. Infectious diseases are conditions caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi that can spread directly or indirectly among individuals. The growing prevalence of infectious diseases is fueled by rising global population density, which heightens transmission risks and facilitates disease spread. Point-of-care tuberculosis ultra-sensitive nucleic acid amplification testing addresses the increasing prevalence of infectious diseases by providing rapid, highly sensitive, and decentralized detection of infectious pathogens, thereby enhancing early diagnosis and disease control measures. For example, in March 2025, the UK Health Security Agency, a UK-based government health authority, reported that tuberculosis cases in England rose by 13% in 2024, reaching 5,480 cases compared to 4,850 cases in 2023. Consequently, the growing prevalence of infectious diseases is propelling the expansion of the point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market.

Leading companies operating in the point-of-care tuberculosis ultra-sensitive nucleic acid amplification test (NAAT) market are focusing on regulatory validation and international prequalification programs to enhance quality assurance, accelerate global adoption, and improve access to high-sensitivity diagnostic solutions. Prequalification refers to a regulatory assessment process that evaluates in vitro diagnostic products for compliance with international standards of quality, safety, and performance, enabling procurement by global health agencies and deployment in resource-limited settings. For example, in December 2024, the World Health Organization, a Switzerland-based intergovernmental organization, announced the first prequalification of an Xpert MTB/RIF, an ultra-tuberculosis diagnostic test, under its regulatory assessment framework. This milestone supports the expansion of reliable and rapid TB detection tools, particularly across low- and middle-income countries. Leveraging advanced nucleic acid amplification technology, cartridge-based automated systems, and rapid result turnaround capabilities, the solution facilitates decentralized testing, improves early case detection, and strengthens drug-resistance identification. It is specifically engineered for deployment in primary healthcare facilities and remote regions with limited laboratory infrastructure, thereby enhancing surveillance capacity, reducing diagnostic delays, and supporting global tuberculosis control and antimicrobial resistance management initiatives.

In March 2023, the Global Fund to Fight AIDS, Tuberculosis, and Malaria, a Switzerland-based government agency; the United States Agency for International Development (USAID), a US-based government agency; and Stop TB, a Switzerland-based non-profit organization, announced a partnership with Molbio Diagnostics Pvt. Ltd. to expand global access to rapid molecular diagnostic tests for tuberculosis. Through this partnership, the organizations aim to increase the availability of point-of-care, ultra-sensitive nucleic acid amplification tests (NAATs) for TB detection, especially in high-burden and resource-limited regions, thereby enhancing early diagnosis and treatment initiation efforts globally. Molbio Diagnostics Pvt. Ltd. is an India-based manufacturer of portable, cartridge-based molecular platforms (such as Truenat) engineered for rapid, near-patient TB detection using nucleic acid amplification technology.

Major companies operating in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, QIAGEN N.V., SD BIOSENSOR Inc., Eiken Chemical Co. Ltd, Oxford Nanopore Technologies Ltd, Molbio Diagnostics Limited, Sansure Biotech Inc., CapitalBio Corporation, QuantuMDx Group Limited, Tata Medical Diagnostics Limited, Ustar Biotechnologies, Mylab Discovery Solutions Private Limited, GenoScreen SAS, Co-Diagnostics Inc., Longhorn Vaccines Diagnostics LLC, Akonni Biosystems Inc., Zeesan Biotech Co. Ltd, Redcliffe labs.

North America was the largest region in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market consists of revenues earned by entities by providing services such as regulatory compliance support services, distribution and logistics services, and after-sales support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market also includes sales of disposable pipette tips, microfluidic chips, control materials, and calibration kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

A point-of-care tuberculosis ultra-sensitive nucleic acid amplification test is a rapid molecular diagnostic tool developed to detect Mycobacterium tuberculosis genetic material near or at the patient’s care setting. Using advanced amplification methods, it identifies very low bacterial loads with high sensitivity and specificity, enabling early and reliable diagnosis. Designed to be compact and automated, this test delivers fast results, supporting timely clinical decisions and effective disease management.

The key technologies of point-of-care tuberculosis ultra-sensitive nucleic acid amplification tests include polymerase chain reaction (PCR)-based nucleic acid amplification testing, isothermal amplification, and other methods. PCR-based nucleic acid amplification testing is a molecular technique that rapidly amplifies and detects specific DNA or RNA sequences to identify pathogens with high sensitivity. Product types include instruments, reagents and consumables, and software, and testing is performed on samples such as sputum, blood, urine, and others. End users include hospitals and clinics, diagnostic laboratories, research institutes, and other organizations.

Tariffs have affected the point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market by increasing the cost of importing high-precision instruments, reagents, and consumables. This impact is most pronounced in regions such as North America and Europe, which rely on imports for advanced diagnostic devices. While tariffs have slowed procurement and adoption in some healthcare facilities, they have also encouraged local manufacturing, innovation in cost-efficient solutions, and diversification of supply chains, ultimately enhancing market resilience.

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market research report is one of a series of new reports that provides point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market statistics, including point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) industry global market size, regional shares, competitors with a point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market share, detailed point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market segments, market trends and opportunities, and any further data you may need to thrive in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) industry. This point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.